

GP-TCM RA Elections - President-Elect and Members of Board of Directors (BoD)

With the approval of the current GP-TCM RA Board of Directors (BoD), the Secretariat is 3rd GP-TCM RA election for nine BoD members, including President-Elect.

Standing for President-Elect

Professor Lu Aiping



Self-introduction

Professor Lu Aiping is Chair Professor & Dean of School of Chinese Medicine, Hong Kong Baptist University, and Chair Professor in Shanghai University of Traditional Chinese Medicine. Prof. Lu is also the recipient of the Distinguished Young Scholar in National Science Foundation of China (NSFC) in 2007. Besides, he also as Member of Medical Advisory Committee of National Natural Science Foundation of China (NSFC), Member of Chinese Pharmacopoeia Commission and Vice-Chairman, Terminology of Traditional Chinese Medicine Sub-Committee, China National Committee for Terms in Sciences and Technologies (CNCTST). Also he has been appointed as Head & Spokesperson of the China Delegation, International Organization for Standardization Technical Committee on TCM (ISO/TC249) since 2009. His research interests mainly focus on the translational research in Chinese medicine, including pharmacological and clinical evaluation on rheumatoid arthritis with traditional Chinese medicine pattern diagnosis and interventions, and development of new drugs based on Chinese medicines. Also he is actively involving the research on the standardization of Chinese medicine and strategic plan research for Chinese medicine development in China. Prof Lu has published more than 30 books and over 500 articles, including 200 articles in SCI journals such as Nature Medicine, Nature Communication, Biomaterials, and Briefings in Bioinformatics.

Personal statement (200 words)- Why have you applied for the position? What will you do if elected?

Developing, disseminating and implementing good practice (GP) are necessary to high-quality evidence-based research of traditional Chinese medicine (TCM). In the past years, GP in TCM studies was moving towards a new age of discovery by maturing its collaborations and activities. In future, it is important to incorporate creative and innovative questions into TCM studies by improving collaboration among multinational interdisciplinary researchers and physicians. It is highly recommended that we make GP-TCM became a venue to nurture young researchers, to foster good practice in the conduct and reporting of their research. I hope GP-TCM became an open and lively environment featured by cross-disciplinary study, and research exchange opportunities, even industrial collaboration.

I will also aim to expand clinical data access to researchers and enable future discoveries of links between omics and indications for herbal formulas. Eventually, steady sustainable development of TCM studies will improve data confidence internationally. I would like to express my enthusiasm for the advances of pharmacological evaluation on herbal mixtures and clinical evaluation of CHMs. I look forward to working with other GP-TCM members that I have worked with before and I am anxious to meet those I have not.

Standing for positions on the Board of GP-TCM RA

1. Professor Pierre Duez



Self-introduction

PhD in Pharmaceutical Sciences (Toxicology), Pierre Duez heads a teaching and research department in the Université de Mons (Faculty of Medicine and Pharmacy); he is teaching Pharmacognosy, Pharmacology, Nutrition and bibliographical tools, both in theory and practice. His laboratory has access to the main chromatographic and spectroscopic techniques and welcomes Belgian and foreign PhD students. Specialized in the study of natural products, in bioguided fractionation of medicinal plant extracts and in the analysis of phytodrugs, herbal nutritional supplements and food constituents, the team concentrates on the elucidation of DNA repair modulators from food and medicinal plants. Pierre Duez is member of the European Pharmacopoeia TCM working party, of the Belgian Commission of Pharmacopoeia, of the Belgian Commission for Registration of Herbal Medicines. He is active in development cooperation with Algeria, Argentina, Germany, Burkina Faso, France, Uganda, UK, DR Congo, PR China, Rwanda, Madagascar, Vietnam. Member of the GP-TCM consortium, he is currently Board Member and Chair of the Pharmacology & Toxicology Interest Group for the GP-TCM RA. He is (co-)supervisor of 19 defended theses, co-editor of 1 book, co-author of 8 book chapters, 142 scientific papers, 1 report for the European Development Fund and 246 communications in national and international meetings. He has organized the 2015 GP-TCM RA meeting in Mons, Belgium.

Personal statement (200 words)- Why have you applied for the position? What will you do if elected?

My interest in TCM dates back to 1992 with the affair of "Chinese herbs nephropathies" in which I was closely associated for elucidating the adulteration responsible for intoxications. The GP-TCM consortium has allowed me to delve much deeper in the various problems associated with TCM documentation, quality and toxicology, while meeting leading experts in the field. As GP-TCM RA Board Member, I have tried to contribute to maintain the group and to further advance its unique possibilities. As Chair of the Pharmacology & Toxicology Interest Group, I have summarized the challenges associated with herbal medicines and established a plan for action (<http://www.gp-tcm.org/work-packages/wp3-functional-genomics-in-toxicology-study-of-chinese-herbal-medicines/>). Besides further contributing to developing the Association, one of my major interests resides in joining the forces of the Pharmacology & Toxicology Interest Group members to begin developing concerted actions, with concern in relating quality and regulatory aspects. These are

key issues for acceptance of TCMs in Europe. I do not forget that medicinal herbs are used throughout the world, either as complementary and alternative medicines or as primary care resources. The latter is particularly the case in Sub-Saharan Africa where 80% of people rely on traditional medicine for healthcare. Introduction of young scientists from all over the world to the advances of TCM will help in improving the current standards of care in developing countries by implementing local strategies for herbs quality control and safety assessment.

2. Professor Rudi Bauer



Self-introduction

Rudolf Bauer studied pharmacy at University of Munich and graduated as Ph.D. in 1984; 1993-2002 associate professor at the Institute of Pharmaceutical Biology, University of Düsseldorf; since 2002 professor of pharmacognosy at University of Graz, Austria, 2004 Head of Institute of Pharmaceutical Sciences at University of Graz; since 2008 head of TCM Research Center Graz – medicinal plant research. Guest professor at School of Chinese Materia Medica, Beijing University of Chinese Medicine; Guangxi Botanical Garden of Medicinal Plants and Institute of Guangxi Medicinal Plants, Nanning; Institute of Medicinal Plant Development, China Academy of Medical Sciences, Beijing; Chengdu University of TCM; Heilongjiang University of CM, Harbin; Changchun University of CM. Recipient of Egon-Stahl-Award of the Society for Medicinal Plant and Natural Product Research (GA) and Norman Farnsworth Excellence in Botanical Research Award. Associate Editor in Chief of Chinese Journal of Natural Medicines and World Journal of Traditional Chinese Medicine (WJTCM). Member of the expert group on Chinese herbs of the European Pharmacopoeia. President of the Society for Medicinal Plant and Natural Products Research (GA) for six years, founding president of GP-TCM Research Association, and currently president of the International Society for Ethnopharmacology. Long experience in natural product chemistry; ca. 340 scientific publications.

Personal statement (200 words)- Why have you applied for the position? What will you do if elected?

I have been committed to best practice in TCM research since 25 years, and have always supported the GP-TCM project. Finally I have served for two years as the founding president of GP-TCM Research Association and another two years as past president in the ExC of GP-TCM RA. During this time I have been organizing the 2nd annual meeting of GP-TCM RA in Graz in 2013. I now want to continue serving our Association mainly in the fields of pharmacological research, quality control, and regulatory affairs. I also would like to act as a link of GP-TCM RA to other organizations, like GA, ISE, and the Consortium for the Globalization of Chinese Medicine, in order to establish a powerful network. A further goal is to stimulate international research collaborations in the field of TCM and to tighten the bonds between Europe and China.

3. Professor MONIQUE S.J. SIMMONDS OBE, JP, BSc, PhD, FLS, FRES, FWIF



Self-introduction

I have 30 years experience of research into different aspects of plant and fungal chemistry with an emphasis on the economic value of natural products, including quality control of medicinal plants. I am involved in the development of appropriate methods for the quality control of plants entering the trade and work with government bodies and industry. I am an international member of advisory committee for Hong Kong Dept. of Health, Pharmacopoeia, a member of the British Pharmacopoeia Commission, Dept of Health, UK and Chairman Elect, Expert Advisory Group Herbal and Complementary Medicines (Dept of Health, UK). Although my research is mainly on the chemistry of plants I have close research interactions with those developing DNA methods especially new methods that can link identification with quality. Within TCM I have worked closely with colleagues to support the collection of relevant material that can be used to authenticate plants and fungi used in TCM. I have over 360 publications and have supervised 37 PhD students.

Personal statement (200 words)- Why have you applied for the position? What will you do if elected?

I would hope to co-ordinate a conference for GP-TCM RA at the Royal Botanic Gardens, Kew UK in 2017. With an emphasis on different aspects of quality control, especially with the increased interest in the use and sale of granulated preparations. What impact does this method of preparation have on the chemistry and efficacy of TCM preparations? I am also keen to discuss what impact of changes in land use in China and climate change is having on the sustainable supply of plants and fungi used in TCM and the need to get more material into cultivation.

As Editor-in-Chief of Biochemical Systematics and Ecology I have been promoting the submission of manuscripts that illustrate the importance of systematics in developing appropriate methods (Chemistry and DNA) to differentiate between adulterants and substitutes used in TCM. I aim to continue to do this with a special issue of the journal at the end of 2017.

I am also keen to promote the science of TCM plants in Europe. I also think it is important to maintain an international composition of the GP-TCM RA board which helps retain the EU-China composition of this society.

4. Professor Thomas Efferth



Self-introduction

Professor Dr. Prof. h. c. mult. Thomas Efferth is chair of the Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany. He is biologist by training (Technical University of Darmstadt, Germany). His doctoral thesis was completed at the German Cancer Research Center (DKFZ), Heidelberg, Germany (1990). Dr. Efferth was awarded the Ludolf-Krehl-Prize of the Southwest German Association for Medicine (1991), the Willmar-Schwabe-Award of the German Society for Medicinal Plant Research (2006), the citizen medal of the City of Heidelberg, Germany (2008), the CESAR Award for Translational Oncology (2011), and the SCENTEDdrop Award on medicinal and fragrant herbs (2015). He headed a research group for Pharmaceutical Biology at DKFZ (2005-2009) and was associate professor (apl) at the University of Heidelberg (2007-2009). In 2009, he took over the Chair of Pharmaceutical Biology (full professorship) at the Johannes Gutenberg University, Mainz. Furthermore, he is honorary professor at the Northeast Forestry University, Harbin, and at the Zhejiang Chinese Medical University, Hangzhou, China. Moreover, he is visiting professor at the Zhejiang University of Science and Technology, Hangzhou, China.

Thomas Efferth has published >440 PubMed-listed papers and in peer-reviewed journals in the field of cancer research, pharmacology, and natural products (Hirsch-factor: 60; citation rate: >15,000) and a textbook on 'Molecular Pharmacology and Toxicology' (Springer Publisher; 2006). He holds 7 patents. The scientific results were communicated in over 180 oral presentation and invited lectures and over 150 poster presentations at national and international conferences and meetings. He is editor-in-chief, co-editor, associate editor and editorial board member of 30 scientific journals and scientific advisory board member of the German Pharmaceutical Society and several other institutions. Seven of his former lab members promoted to associate or assistant professors. The focus of Dr. Efferth's research is on tumor pharmacology, pharmacogenomics, and the development of novel options for treatment and diagnosis of cancer. A major topic is research on chemical entities from natural sources.

For more details see: <http://www.pharmazie.uni-mainz.de/Ak-Efferth/index.php>

Personal statement (200 words)- Why have you applied for the position? What will you do if elected?

My personal motivation to apply as member of the Board of Directors is mainly due to the fact that I have been working in the field of natural products with a focus on Chinese herbs for more than 20 years. I strongly felt that Chinese medicine and in a broader sense Traditional Medicine in general needs to be further promoted in the scientific world. The therapeutic potential of traditional medicines needs to be systematically explored for the sake of millions of patients worldwide. To reach this goal, scientific platforms are needed for collaboration and scientific exchange. GP-TMR provides an exquisite opportunity for such a platform. For this reason, I like to contribute to realize the major goals of GP-TMR. From a personal point of view, I estimate the following topics of special relevance:

1. Strengthening interdisciplinary approaches between basic research and medical application.
2. Integration of traditional medicines into academic school medicine. To realize this goal the rules of evidence-based medicine should be applied to traditional medicines.
3. My personal research focus is on cancer, the elucidation of molecular modes of action, pharmacogenomics and strategies for therapeutic intervention of cancer by phytotherapy and phytochemicals derived thereof.
4. Fostering careers of young researchers in traditional medicine.

5. Professor Rob Verpoorte

Natural Products Laboratory, IBL, Leiden University, The Netherlands



Self-introduction

Emeritus Professor of Pharmacognosy at Natural Products Laboratory, IBL, Leiden University, pharmacist from origin, I have worked on many aspects of medicinal plants and plant secondary metabolism. In the past years the application of systems biology approaches using metabolomics to study activity and quality of medicinal plants and the role of secondary metabolism in plants has been my major field of interest. I published more than 740 papers and 4 books in the field of natural products.

Personal statement (200 words)- Why have you applied for the position? What will you do if elected?

In different way I served the scientific community: as Chairman of the Phytochemical Society of Europe; in the organization of a number of international scientific meetings; and as reviewer for many journals and Scientific councils. Since May 1, 2011 I am retired, but will continue to work the coming years to supervise my last 7 PhD-students and finalize the various ongoing projects and I finished my activities as Editor-in-Chief of Journal of Ethnopharmacology but will continue as editor-in chief of Phytochemistry Reviews and executive-Editor of Biotechnology Letters.

6. Dr. Qihe Xu



Self-introduction:

Dr. Qihe Xu, GP-TCM RA Life Member & Newsletter Co-editor, Co-Director of King's Centre for Integrative Chinese Medicine (CICM), Senior Lecturer in Renal Medicine, Pharmacology Admissions Tutor and Organiser of MSc/MRes Pharmacology Projects at King's College London (KCL). My research has been funded by National Natural Science Foundation of China, International Society of Nephrology, Royal Society, Kidney Research UK, British Heart Foundation, as well as UK, US and EU governments. In 2009-2012, I coordinated the FP7 GP-TCM Project. In 2012-2014, I served as Vice President & Vice Secretary-General of the GP-TCM RA. I earned my MBBS, MD and PhD from Xinxiang Medical College, Beijing Medical University and the General Hospital of the Chinese PLA, respectively. My past honours included a meritorious medal from the Chinese PLA, a national award for scientific & technological advances in China, a scholarship and a fellowship from the International Society of Nephrology and a Courtesy Associate Fellowship of the US National Institutes of Health. Other past experiences included Secretary-General, Chinese Students & Scholars Association in the UK, President of the Chinese Life Scientists Society in the UK and Founder Vice-President of the Academy of Life Sciences for Chinese in the UK, etc.

Personal statement (200 words)- Why have you applied for the position? What will you do if elected?

I put myself forward because I believe in the potential of the GP-TCM RA and feel that the young Association deserves my continued support. After leading the GP-TCM Project and serving the GP-TCM RA for a term, I stepped down from the Board in 2015 to devote myself to disseminating, through GP-TCM RA Newsletters, the GP-TCM consensuses (*J Ethnopharmacol.* 2012;140:458), the GP-TCM RA 3Is principle (*BMC Complement Altern Med.* 2013;13:132) and the latest developments in TCM, science and EU-China cooperation, and to founding King's CICM, an official KCL initiative since 2013.

Thanks to the painstaking efforts of my team members, King's CICM has recently been awarded priority for fundraising, outcomes of which will affect the future of the initiative. Nonetheless, to succeed, CICM must build on the GP-TCM consensuses and the GP-TCM RA 3Is principle. So must the GP-TCM RA.

If elected, I will strive for promoting closer links between the Association and its members, enhancing the capability of the Association to serve its members better and facilitating the work of Interest Groups and focused collaborations.

Despite Brexit and any other uncertainties, my belief in good practice, the power of collaborations and the value of integrative Chinese medicine stay.

7 . Prof. Clara Bik-San LAU BPharm, PhD, MRPharmS



Self-introduction

Professor Clara Lau is the Associate Director of the Institute of Chinese Medicine at The Chinese University of Hong Kong. She also serves as the Associate Director of the Partner State Key Laboratory of Phytochemistry and Plant Resources in West China (CUHK). She has a courtesy appointment as Associate Professor at the School of Chinese Medicine, CUHK and has served as Deputy Program Director/Program Director (2005-2015) of a part-time MSc in Chinese Medicines and Herbal Drugs. With BPharm and PhD in Pharmacy (Pharmacognosy) from King's College London, University of London, United Kingdom, she has a continuous interest in medicinal plants (western herbals and traditional Chinese herbal medicines) and has over 20 years' experience in natural products research. Her major research areas include investigations on potential anti-cancer and anti-diabetic activities of natural products. She has published over 180 refereed journal articles. She currently serves as member of ChP-USP Advisory Group on Monographs for Traditional Chinese Medicine Ingredients and Products; Deputy Secretary General of The Consortium for Globalization of Chinese Medicine; Executive Committee member of Modernized Chinese Medicine International Association; Advisor for Chinese Medicine Council of Hong Kong on Registration of Proprietary Chinese Medicines; and Editorial Board member of journal "Chinese Medicine".

Personal statement (200 words)- Why have you applied for the position? What will you do if elected?

Having attended four (2nd to 5th) annual meetings of the GP-TCM Research Association, being awarded with best poster prizes in two of these meetings, and also being an invited speaker in the most recent annual meeting, I would like to join as a member of Board of Directors in order to contribute more towards this influential Association. If I got elected as a member of BoD, I would like to contribute in the following ways:

- a) Being an academia, I have taught Pharmacognosy for over 10 years and successfully supervised/co-supervised 9 postdoctoral fellows, 8 M.Phil. and 19 Ph.D. students in TCM research. I will continue to nurture young TCM researchers and coach them in publishing TCM research findings.
- b) Being an active researcher in TCM for over 16 years, with strong research networks in TCM/natural products field all over the world, plus language fluency in English, Cantonese and Putongua, I am certain that I can help in facilitating interdisciplinary and interregional research collaborations.
- c) With strong administrative and organizational skills, currently serving as board members/executive committee members of various TCM related organizations, I will strive to promote research collaborations among GP-TCM RA and these organizations.

8. Prof Vivian Taam Wong JP MBBS, FRCOG, FFPH, FRCP (London), FRACMA, FHKAM



Self-introduction

- Hon Professor, School of Chinese Medicine, HKU
- Vice President, Modernized Chinese Medicine International Association
- Board of Director, GP-TCM Research Association
- HK Coordinator, Consortium for Globalization of Chinese Medicine
- Council Member, Chinese Association of Integrative Medicine

Key Past Appointments:

- Public Health Specialist, Policy & Research, Population Health & Nutrition, The World Bank
- Chairman, Committee on Safe Motherhood, International Federation of Gynecology & Obstetrics
- Member of various Committees under World Health Organization
- Consultant on Health Project IV & VI in China for the World Bank
- Chief Executive, Hospital Authority, HK
- Hon Advisor in Integrative Medicine, Hospital Authority, HK
- Hon Senior Advisor to Dean of Medical Faculty, the University of HK
- President, HK Association for Integration Chinese-western Medicine

I have been on editorial boards of 6 journals, and published >120 peer-reviewed papers. I set up the unique HK-wide Research Ethics Committee system & standards enabling multicentre trials as well as the high quality network of Chinese Medicine Centres for Training and Research in each district in HK. She is now steering education, research and knowledge transfer to support collaboration among CM and western medicine practitioners.

Personal statement (200 words)- Why have you applied for the position? What will you do if elected?

I was involved in this movement, as an advisor to the EU FP7 program “GP-TCM in the Post Genomic Era”. Through communicating with the Working Packages, I learnt that there are many scientists deeply committed to the study of ethnopharmacology in general and Chinese medicine in particular. I conducted the first Randomized Controlled Trial in the use of Acupuncture for induction of labour in University of Hong Kong in the 1970s. Over the past 40 years I have been engaging both western and Chinese scientists in research to support “Evidence-based Medicine” which has been turned into “integrated medicine” through the patients’ own initiative. My qualifications in a number of specialties and wide research interest from hematology, hepatology, virology, perinatology, obstetrics and gynecology facilitated my work in steering education, research and knowledge transfer in Hong Kong as a bridge between China and countries overseas.

I was elected a Director of GP-TCM RA for the past 2 terms, contributing to the expansion of networks and postgraduate research, with a view to help steer the development of Good Practices in the chain to Good Clinical Practice. I would like to contribute my time and expertise in the Acupuncture and Clinical Studies Interest Groups in the coming years.

9. Professor Kelvin Chan



Self-introduction

Having completed the successful Sydney project in TCM as Joint Chair Professor at the University of Sydney & Western Sydney University (WSU), I returned to UK as Visiting Professor in Natural products & TCM Research at Liverpool JM University while maintaining close association as Adjunct Professor of TCM Research at the University of Technology Sydney (UTS) and WSU in 2015, I now have more opportunity to closely link scientists and practitioners engaged in TCM research and products development in both Northern and Southern hemispheres. Initially trained in Industrial Pharmacy, then specialised in Clinical Pharmacology in the UK, I started R&D of TCM at the Chinese University of Hong Kong (1981-1992) while teaching medical pharmacology in orthodox medicine; subsequently I have taught pharmacy, and biomedical sciences in TCM at universities in Hong Kong, UK, UAE and Australia. Research publications include 260 full SCI papers, 3 reference/specialist books in toxic CMM, interactions between pharmaceuticals and TCM products and several monographs of pharmaceutical drugs and CMM, and over 300 international keynotes/presentations at conferences. Current focuses in TCM include: Methodology on QC of Chinese materia medica; 'Omics' approaches in bioactivity screening; Integrating TCM with biomedical medicine research; Promoting education & training curriculum towards integrative medicine.

Personal statement (200 words)- Why have you applied for the position? What will you do if elected?

Being an existing BoD member and Chair of QC Interest Group of the GP-TCM RA I have linked scientists and practitioners engaged in TCM focusing on QC aspects of TCM in both Northern- and Southern- hemispheres apart from recruitment of members for GP-TCM RA. My networking activities in Australia, China, Europe, Hong Kong, UAE, and UK will help to promote the Association in both hemispheres. In all my keynote and conference presentations I have focused on the key issues for global recognition of TCM practice and products development via quality control and quality assurance for practice and products development. My research focusing on quality CMM and PCM linking with future harmonised regulatory issues are needed for good quality products for TCM practice in future integrative healthcare.

Training of human resources in these areas needs more activities. I recognized the 'Belt and Road' concept initiated by President Xi, which will encourage not only global trade development but also mobilize TCM R&D extending to Southern Hemisphere and worldwide. I will also work hard following the 13-5 initiative with key research institutes/authorities over QC requirements on TCM as these will provide good interacting opportunities for research institutes outside China Mainland towards TCM globalisation.

10. Mr. Chan Yu Ling, Abraham



Self-introduction

I am the founder and Chairman of PuraPharm. PuraPharm has dedicated itself to the modernization and internationalization of traditional Chinese medicine (TCM). It is a leading company engaged in the R&D, production, sale of concentrated Chinese Medicine granules (CCMG) products. PuraPharm has its TCM research & production facilities in Guangxi, China which complies with the PRC Good Manufacturing Practice (GMP) standards and the Australia's Therapeutic Goods Administration (TGA) standards. PuraPharm is one of the six companies licensed to make and sell CCMG in China and is China's top five exporters of proprietary Chinese medicine.

I am responsible for the overall strategic planning and operations of the Group's business. I also lead the Group's research development and technological development functions. I have over 25 years of extensive experience in Chinese medicine and healthcare products. I graduated from the University of Toronto in Canada with a Bachelor's Degree in Applied Sciences in 1982. I was accredited as a chartered engineer in the United Kingdom in October 1989 and was accredited as a professional engineer in Ontario, Canada in January 1989. I hold positions in various organizations:

<u>Organizations and associations</u>	<u>Position</u>
Chinese Medicine Development Committee of HKSAR	Member
Hong Kong Advisory Council on Food and Environmental, HKSAR	Member
Modernized Chinese Medicine International Association Ltd.	Founding council member
School of Pharmacy of The Chinese University of Hong Kong	Advisory committee member
The International Society of Oriental Medicine	Board member (Hong Kong representative)
Bachelor of Pharmacy Programme of the Department of Pharmacology and Pharmacy, Faculty of Medicine, the University of Hong Kong	Advisory board member
The Association of Hong Kong and Kowloon Practitioners of Chinese Medicine Limited	Advisor
The Hong Kong T. C. M. Orthopaedic and Traumatic Association Ltd.	Advisor

Personal statement (200 words)- Why have you applied for the position? What will you do if elected?

Nowadays, people are becoming increasingly health-conscious and quest for quality health products. As a founder of modernizing Chinese medicine company since 1998, my vision to modernize Chinese Medicine in the way that can help millions of people to have better health never change. I am continuing to pioneer the modernization and internationalization of TCM, to offer professional, quality, effective, safe and reliable products through the oriental wisdom of TCM, innovation and pioneering research. My vision coincides with the objective of Good Practice in Traditional Chinese Medicine (GP-TCM) Research Association to promote high-quality evidence-based research of TCM through developing, disseminating and implementing good practice.

PuraPharm has a strong scientific advisory committee, with world-renowned scientists advising us on the prevailing research trends and the updated technologies for our product development. Besides, we collaborated with different universities in Hong Kong, Canada and Australia for research projects. It can be a good platform to strengthen international collaborations in TCM research and development. PuraPharm also fully committed to the establishment of quality standards for CCMG products through our cooperation with the China's Food & Drug Administration (CFDA), the Committee for the Chinese Pharmacopoeia and major universities in Hong Kong, the PRC and overseas countries. We are the only CFDA-licensed CCMG product manufacturer who has received United States Pharmacopeia (USP) verification of its CCMG products according to the U.S. Pharmacopeial Convention. We currently collaborate with the USP in the standardization of CCMG products. This is what we can do for the association to advocate high-quality evidence-based research and development on TCM.